BofA analyst Jason Gerberry downgraded Allogene Therapeutics to Underperform from Buy with a $9 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLO:
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Oppenheimer emerging biotech analysts to hold analyst/industry conference call
- Allogene unveils Dagger technology during R&D showcase
- Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
- Allogene Therapeutics to hold a research and development showcase